Prediction of Resistance to 177Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers

Conclusion: Our analyses indicate that ctDNA assays may contain specific biomarkers predictive of response or resistance for 177Lu-PSMA–treated mCRPC patients. Additional confirmatory studies are required before clinicians can use these findings to make personalized treatment decisions.

Source: Journal of Nuclear Medicine - November 2, 2023 Category: Nuclear Medicine Authors: Sartor, O., Ledet, E., Huang, M., Schwartz, J., Lieberman, A., Lewis, B., Layton, J., Barata, P., Jang, A., Hawkins, M., Pocha, O., Lanka, S., Harris, K. Tags: Brief Communications Source Type: research